BACKGROUND: Mechanical @entity158 @entity56 associated with physical @entity130 to peripheral nerve depends on T-helper (Th) cells expressing the algesic cytokine, interleukin (IL)-17A. Fibronectin (FN) isoform alternatively spliced within the IIICS region encoding the 25-residue-long connecting segment 1 (CS1) regulates T cell recruitment to the sites of @entity32 . Herein, we analyzed the role of CS1-containing FN (FN-CS1) in @entity7940 expression and @entity158 after @entity1897 . METHODS: Mass spectrometry, immunoblotting, and FN-CS1-specific immunofluorescence analyses were employed to examine FN expression after @entity8638 ( @entity8638 ) in @entity35 sciatic nerves. The acute intra-sciatic nerve injection of the synthetic CS1 peptide (a competitive inhibitor of the FN-CS1/a4 integrin binding) was used to elucidate the functional significance of FN-CS1 in mechanical and thermal @entity158 @entity56 and @entity7940 expression (by quantitative Taqman RT-PCR) after @entity8638 . The CS1 peptide effects were analyzed in cultured primary Schwann cells, the major source of FN-CS1 in @entity8638 nerves. RESULTS: Following @entity8638 , FN expression in sciatic nerve increased with the dominant FN-CS1 deposition in endothelial cells, Schwann cells, and macrophages. Acute CS1 therapy attenuated mechanical @entity1931 ( @entity158 from innocuous stimulation) but not thermal @entity1931 and reduced the levels of @entity7940 expression in the injured nerve. CS1 peptide inhibited the LPS- or starvation-stimulated activation of the stress ERK/MAPK pathway in cultured Schwann cells. CONCLUSIONS: After physical @entity130 to the peripheral nerve, FN-CS1 contributes to mechanical @entity158 @entity56 by increasing the number of @entity7940 -expressing (presumably, Th17) cells. CS1 peptide therapy can be developed for pharmacological control of @entity9 .

The alternatively spliced fibronectin CS1 isoform regulates @entity7940 levels and mechanical @entity1931 after XXXX .

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity7940 :: ('301289(Tax:10116)', 'Gene') :: ['IL-17A'] @entity1931 :: ('MESH:D006930', 'Disease') :: ['allodynia', 'hyperalgesia'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral nerve damage'] @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity35 :: ('10116', 'Species') :: ['rat'] @entity8638 :: ('MESH:D020208', 'Disease') :: ['chronic constriction injury', 'CCI'] @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain'] @entity130 :: ('MESH:D014947', 'Disease') :: ['trauma']
@entity1897 :: (MESH:D010523,Disease) :: ['peripheral nerve injury']
